China Medical System Holdings Ltd. プレスリリース一覧

China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..

China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST

China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..

CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST


もっと見る >>